Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study).
Fernández Liguori N, Klajn D, Acion L, Cáceres F, Calle A, Carrá A, Cristiano E, Deri N, Garcea O, Jaureguiberry A, Onaha P, Patrucco L, Riccio P, Rotta Escalante R, Saladino Ml, Sinay V, Tarulla A, Villa A. Fernández Liguori N, et al. Among authors: carra a. Mult Scler. 2009 May;15(5):555-62. doi: 10.1177/1352458509102366. Epub 2009 Mar 19. Mult Scler. 2009. PMID: 19299437
Argentine Patagonia: prevalence and clinical features of multiple sclerosis.
Melcon MO, Gold L, Carrá A, Cáceres F, Correale J, Cristiano E, Fernández Liguori N, Garcea O, Luetic G, Kremenchutzky M; Patagonia Multiple Sclerosis Research Project. Melcon MO, et al. Among authors: carra a. Mult Scler. 2008 Jun;14(5):656-62. doi: 10.1177/1352458507085801. Mult Scler. 2008. PMID: 18566029
Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.
Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; Rebif New Formulation Study Group. Giovannoni G, et al. Mult Scler. 2009 Feb;15(2):219-28. doi: 10.1177/1352458508097299. Epub 2008 Aug 28. Mult Scler. 2009. PMID: 18755819 Clinical Trial.
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
Fragoso YD, Boggild M, Macias-Islas MA, Carra A, Schaerer KD, Aguayo A, de Almeida SM, Alvarenga MP, Alvarenga RM, Alves-Leon SV, Arruda WO, Brooks JB, Comini-Frota ER, Ferreira ML, Finkelsztejn A, Finkelsztejn JM, de Freitas LD, Gallina AS, da Gama PD, Georgetto S, Giacomo MC, Gomes S, Gonçalves MV, Grzesiuk AK, Kaimen-Maciel DR, Lopes J, Lourenco GA, Malfetano FR, Morales NM, Morales Rde R, Oliveira CL, Onaha P, Patroclo C, Ribeiro SB, Ribeiro TA, Salminen HJ, Santoro P, Seefeld M, Soares PV, Tarulla A, Vasconcelos CC. Fragoso YD, et al. Among authors: carra a. Clin Neurol Neurosurg. 2013 Feb;115(2):154-9. doi: 10.1016/j.clineuro.2012.04.024. Epub 2012 May 26. Clin Neurol Neurosurg. 2013. PMID: 22633835
Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.
Finkelsztejn A, Gabbai AA, Fragoso YD, Carrá A, Macías-Islas MA, Arcega-Revilla R, García-Bonitto J, Oehninger-Gatti CL, Orozco-Escobar G, Tarulla A, Vergara F, Vizcarra D. Finkelsztejn A, et al. Among authors: carra a. Arq Neuropsiquiatr. 2012 Oct;70(10):799-806. doi: 10.1590/s0004-282x2012001000009. Arq Neuropsiquiatr. 2012. PMID: 23060107 Free article.
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.
Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G. Kuhle J, et al. Among authors: carra a. Mult Scler. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13. Mult Scler. 2015. PMID: 25680984
Biological and nonbiological complex drugs for multiple sclerosis in Latin America: regulations and risk management.
Carrá A, Macías Islas MA, Tarulla A, Bichuetti DB, Finkelsztejn A, Fragoso YD, Árcega-Revilla R, Cárcamo Rodríguez C, Durán JC, Bonitto JG, León R, Oehninger Gatti C, Orozco G, Vizcarra Escobar D. Carrá A, et al. Expert Rev Neurother. 2015 Jun;15(6):597-600. doi: 10.1586/14737175.2015.1042456. Epub 2015 Apr 30. Expert Rev Neurother. 2015. PMID: 25924772
133 results